NCT04544995 - Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 19, 2021

Primary Completion Date

April 23, 2025

Study Completion Date

April 23, 2025

Conditions

Neoplasms

Interventions

DRUG

Niraparib (Tablet for oral suspension)

Niraparib will be administered as TfOS (Tablet for oral suspension)

DRUG

Dostarlimab

Dostarlimab will be administered as IV infusion

DRUG

Niraparib (Tablet)

Niraparib will be administered as tablet

Trial Locations (15)

13005

GSK Investigational Site, Marseille

28009

GSK Investigational Site, Madrid

28046

GSK Investigational Site, Madrid

46026

GSK Investigational Site, Valencia

62500

GSK Investigational Site, Brno

69373

GSK Investigational Site, Lyon

75248

GSK Investigational Site, Paris

94805

GSK Investigational Site, Villejuif

150 06

GSK Investigational Site, Prague

08035

GSK Investigational Site, Barcelona

08950

GSK Investigational Site, Barcelona

B4 6NH

GSK Investigational Site, Birmingham

G51 4TF

GSK Investigational Site, Glasgow

NW1 2PG

GSK Investigational Site, London

SM2 5PT

GSK Investigational Site, Sutton